Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo
Key PointsAbbVie’s ABBV-466 nearly doubled Skyrizi’s Crohn’s remission rate in a Phase 2 study.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.